Psoriasis Clinical Trial Landscape
Data updated: May 20, 2026
1,019 clinical trials tracked since 2008
Psoriasis is a chronic autoimmune disease that primarily affects the skin, causing inflammation and the formation of thick, scaly patches. It affects millions worldwide and presents a significant clinical challenge. The clinical trial landscape for psoriasis immunology is active, with 1,019 trials registered since 2008, and 133 currently active. The majority of these active trials are in Phase 3 (55 trials), followed by Phase 2 (35 trials), Phase 4 (32 trials), and Phase 1 (20 trials). This distribution suggests a strong focus on late-stage development and post-market studies. Among industry sponsors, Johnson & Johnson leads with 6 active trials, followed by Bristol-Myers Squibb, UCB Biopharma SRL, Takeda, and Oruka Therapeutics, Inc., each sponsoring 4 active trials. The high number of Phase 3 trials indicates a mature pipeline with numerous therapies nearing potential market availability.
132 active
/
1019 total (since 2008)
20
Phase 1 Active
221 total
35
Phase 2 Active
324 total
53
Phase 3 Active
328 total
33
Phase 4 Active
188 total
Top Industry Sponsors
Sorted by active Active Done Failed
Johnson & Johnson 6 18 1
Bristol-Myers Squibb 4 15 3
UCB Biopharma SRL 4 13 0
Oruka Therapeutics, Inc. 4 0 0
Takeda 3 5 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06295692 ACTIVE NOT RECRUITING
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Janssen Pharmaceutical K.K. n=19
NCT06425549 RECRUITING
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL n=168
NCT03451851 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
Janssen Research & Development, LLC n=120
NCT07250802 RECRUITING
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Takeda n=110
NCT07116967 RECRUITING
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb n=3,040
+ 323 more Phase 3 trials — see full database below
Psoriasis — Trials Started by Year (last 10 years)
2016 80
2017 65
2018 69
2019 63
2020 40
2021 52
2022 50
2023 51
2024 45
2025 55
2026 24
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Johnson & Johnson 25
Bristol-Myers Squibb 22
UCB Biopharma SRL 17
Oruka Therapeutics, Inc. 4
Takeda 8
InventisBio Co., Ltd 4
Hansoh BioMedical R&D Company 4
Eli Lilly 34
Amgen 30
Bausch Health Americas, Inc. 20
Active Trials by Phase
Phase 1 20
Phase 2 35
Phase 3 53
Phase 4 33
Enrollment Size Distribution
1-50 382
51-200 300
201-500 197
501-1k 80
1k+ 32
All Industry Sponsors
Sorted by active Active Done Failed
Johnson & Johnson 6 18 1
Bristol-Myers Squibb 4 15 3
UCB Biopharma SRL 4 13 0
Oruka Therapeutics, Inc. 4 0 0
Takeda 3 5 0
InventisBio Co., Ltd 3 1 0
Hansoh BioMedical R&D Company 3 1 0
Eli Lilly 2 29 3
Amgen 2 26 2
Bausch Health Americas, Inc. 2 14 4
Boehringer Ingelheim 2 13 1
Sun Pharmaceutical Industries Limited 2 6 3
Alumis Inc 2 3 0
Huabo Biopharm Co., Ltd. 2 2 0
Beijing InnoCare Pharma Tech Co., Ltd. 2 1 0
NCT06295692 ACTIVE NOT RECRUITING
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Janssen Pharmaceutical K.K. n=19
NCT06425549 RECRUITING
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL n=168
NCT03451851 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
Janssen Research & Development, LLC n=120
NCT07250802 RECRUITING
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Takeda n=110
NCT07116967 RECRUITING
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb n=3,040
NCT06979453 RECRUITING
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb n=366
NCT07326813 RECRUITING
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
InventisBio Co., Ltd n=477
NCT04123795 ACTIVE NOT RECRUITING
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL n=49
NCT06506916 ACTIVE NOT RECRUITING
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL n=89
NCT07543224 NOT YET RECRUITING
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.
Reistone Biopharma Company Limited n=600
NCT05172726 ACTIVE NOT RECRUITING
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Organon and Co n=58
NCT03997786 ACTIVE NOT RECRUITING
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
Sun Pharmaceutical Industries Limited n=135
NCT06934226 ACTIVE NOT RECRUITING
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Janssen Research & Development, LLC n=752
NCT06846541 ACTIVE NOT RECRUITING
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Alumis Inc n=1,680
NCT06095115 ACTIVE NOT RECRUITING
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
Janssen Research & Development, LLC n=684
NCT07511647 NOT YET RECRUITING
A Phase 3 Clinical Study of QL2106 Injection
Qilu Pharmaceutical Co., Ltd. n=318
NCT06611163 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
Sun Pharmaceutical Industries Limited n=206
NCT06945107 ACTIVE NOT RECRUITING
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. n=308
NCT06095102 ACTIVE NOT RECRUITING
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
Janssen Research & Development, LLC n=311
NCT06143878 ACTIVE NOT RECRUITING
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Janssen Research & Development, LLC n=774
NCT06220604 ACTIVE NOT RECRUITING
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
Janssen Research & Development, LLC n=731
NCT07432854 NOT YET RECRUITING
A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
Dermavon Holdings Limited n=540
NCT06630559 ACTIVE NOT RECRUITING
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
Celltrion n=153
NCT07426120 RECRUITING
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
Psoriasis Research Institute of Guangzhou n=300
NCT06842199 RECRUITING
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
Beijing InnoCare Pharma Tech Co., Ltd. n=383
NCT07357831 RECRUITING
A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=537
NCT07029516 RECRUITING
Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis
Wooshin Labottach Co., Ltd. n=72
NCT07362017 NOT YET RECRUITING
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Vanda Pharmaceuticals n=300
NCT06588283 ACTIVE NOT RECRUITING
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company n=250
NCT06550076 ACTIVE NOT RECRUITING
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
Takeda n=1,950
NCT07265284 RECRUITING
A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. n=104
NCT05565560 ACTIVE NOT RECRUITING
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
Amgen n=17
NCT05981118 ENROLLING BY INVITATION
Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)
Wake Forest University Health Sciences n=40
NCT07130604 RECRUITING
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
InventisBio Co., Ltd n=390
NCT06088199 ACTIVE NOT RECRUITING
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Amgen n=51
NCT06323356 ACTIVE NOT RECRUITING
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Takeda n=18
NCT04036435 ACTIVE NOT RECRUITING
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
Bristol-Myers Squibb n=1,466
NCT04772079 RECRUITING
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb n=153
NCT04862286 ACTIVE NOT RECRUITING
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
AbbVie n=132
NCT06488664 ACTIVE NOT RECRUITING
An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis
AO GENERIUM n=422
NCT06640517 ACTIVE NOT RECRUITING
Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis
Biocad n=140
NCT06982196 ENROLLING BY INVITATION
Sulodexide in Controlling the Recurrence of Psoriasis
Xijing Hospital n=160
NCT06648772 RECRUITING
Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=189
NCT06937060 RECRUITING
Effect of Semaglutide in Patients With Psoriasis and Obesity
The University of Hong Kong n=14
NCT06943950 NOT YET RECRUITING
A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
CSPC Ouyi Pharmaceutical Co., Ltd. n=500
NCT06643260 NOT YET RECRUITING
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
Can-Fite BioPharma n=705
NCT06863493 NOT YET RECRUITING
Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients
SFA Therapeutics n=125
NCT06844799 NOT YET RECRUITING
A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis
Hansoh BioMedical R&D Company n=720
NCT06833307 NOT YET RECRUITING
The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=90
NCT06477536 RECRUITING
Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
Shanghai Huaota Biopharmaceutical Co., Ltd. n=33
NCT06374979 NOT YET RECRUITING
Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis
Second Affiliated Hospital, School of Medicine, Zhejiang University n=50
NCT06672393 NOT YET RECRUITING
A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
Hansoh BioMedical R&D Company n=375
NCT06477237 RECRUITING
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
Huabo Biopharm Co., Ltd. n=400
NCT06398652 COMPLETED
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
Taizhou Mabtech Pharmaceutical Co.,Ltd n=336
NCT06039189 COMPLETED
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
Janssen Research & Development, LLC n=338
NCT06973291 COMPLETED
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Takeda n=606
NCT03370133 COMPLETED
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL n=567
NCT03410992 COMPLETED
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL n=435
NCT07008547 COMPLETED
To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis
SPH-BIOCAD (HK) Limited n=202
NCT03412747 COMPLETED
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL n=478
NCT03536884 COMPLETED
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL n=743
NCT03598790 COMPLETED
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL n=1,353
NCT06586112 COMPLETED
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Alumis Inc n=912
NCT06588738 COMPLETED
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
Alumis Inc n=862
NCT05919082 COMPLETED
A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis
LEO Pharma n=604
NCT03897075 COMPLETED
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Sun Pharmaceutical Industries Limited n=99
NCT05366855 TERMINATED
Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Vanda Pharmaceuticals n=42
NCT05352893 COMPLETED
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Vanda Pharmaceuticals n=45
NCT06011733 COMPLETED
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL n=133
NCT03818035 COMPLETED
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
Janssen-Cilag International NV n=880
NCT01680159 COMPLETED
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
Tanabe Pharma Corporation n=51
NCT06122649 COMPLETED
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
Amgen n=203
NCT04175613 COMPLETED
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
Amgen n=160
NCT05975268 COMPLETED
A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis
Shanghai Junshi Bioscience Co., Ltd. n=747
NCT06108544 COMPLETED
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
Takeda n=1,108
NCT06088043 COMPLETED
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
Takeda n=693
NCT05239039 COMPLETED
An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
Boehringer Ingelheim n=39
NCT05272150 COMPLETED
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
Janssen Research & Development, LLC n=213
NCT05335356 COMPLETED
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
Biocon Biologics UK Ltd n=384
NCT06049810 COMPLETED
IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
Innovent Biologics (Suzhou) Co. Ltd. n=566
NCT03316781 COMPLETED
Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis
Shanghai Henlius Biotech n=262
NCT04053387 COMPLETED
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
Organon and Co n=763
NCT05028582 COMPLETED
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
Arcutis Biotherapeutics, Inc. n=432
NCT03766685 COMPLETED
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
UCB Biopharma SRL n=172
NCT04146558 COMPLETED
Ayurvedic Treatment Package in Plaque Psoriasis
Universität Duisburg-Essen n=90
NCT03983980 COMPLETED
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
Organon and Co n=515
NCT03956355 COMPLETED
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
Organon and Co n=510
NCT04967508 COMPLETED
A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
Samsung Bioepis Co., Ltd. n=503
NCT04435600 COMPLETED
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
AbbVie n=139
NCT03668613 COMPLETED
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
Novartis Pharmaceuticals n=84
NCT05377944 COMPLETED
Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients
Bio-Thera Solutions n=502
NCT05020249 COMPLETED
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL n=47
NCT04305327 TERMINATED
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
LEO Pharma n=12
NCT01195831 COMPLETED
Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis
LEO Pharma n=244
NCT05536726 COMPLETED
A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. n=458
NCT03806790 COMPLETED
Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris
LEO Pharma n=182
NCT01188928 COMPLETED
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
LEO Pharma n=1,152
NCT01866163 COMPLETED
LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris
LEO Pharma n=426
NCT00670241 COMPLETED
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris
LEO Pharma n=458
NCT02668692 COMPLETED
LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis
LEO Pharma n=213
NCT02310646 COMPLETED
Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris
LEO Pharma n=219
NCT00691002 COMPLETED
Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds
LEO Pharma n=1,245
NCT02132936 COMPLETED
LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris
LEO Pharma n=504
NCT00640822 COMPLETED
Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds
LEO Pharma n=782
NCT01007591 COMPLETED
A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas
LEO Pharma n=40
NCT05200247 COMPLETED
An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
Boehringer Ingelheim n=11
NCT06066125 COMPLETED
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis
Akeso n=351
NCT02905331 COMPLETED
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Janssen Research & Development, LLC n=78
NCT04286607 COMPLETED
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Arcutis Biotherapeutics, Inc. n=333
NCT03701763 COMPLETED
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
Amgen n=245
NCT04607980 COMPLETED
A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Amgen n=563
NCT03047395 COMPLETED
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
AbbVie n=2,170
NCT03308799 COMPLETED
A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream
MC2 Therapeutics n=794
NCT05645627 COMPLETED
A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis
Innovent Biologics (Suzhou) Co. Ltd. n=500
NCT05637515 COMPLETED
Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity
Biocon Biologics Inc. n=374
NCT05495568 COMPLETED
To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis
Celltrion n=367
NCT05763082 COMPLETED
Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis
Padagis LLC n=414
NCT05203315 COMPLETED
Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults
Austin Institute for Clinical Research n=21
NCT04713592 COMPLETED
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
AbbVie n=174
NCT05509361 COMPLETED
Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis
Akeso n=950
NCT03721172 COMPLETED
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
Amgen n=595
NCT03777436 COMPLETED
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
Amgen n=289
NCT02982005 COMPLETED
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
Kyowa Kirin Korea Co., Ltd. n=62
NCT02527421 TERMINATED
DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis
Primus Pharmaceuticals n=3
NCT01947491 COMPLETED
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Primus Pharmaceuticals n=394
NCT01967069 COMPLETED
A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis
Primus Pharmaceuticals n=277
NCT04237116 TERMINATED
A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
Novartis Pharmaceuticals n=10
NCT05073315 COMPLETED
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
Amgen n=425
NCT04785326 COMPLETED
Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Dong-A ST Co., Ltd. n=598
NCT04839328 COMPLETED
A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Tianjin Hemay Pharmaceutical Co., Ltd n=306
NCT04761627 COMPLETED
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Amgen n=494
NCT02660580 COMPLETED
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
Fresenius Kabi SwissBioSim GmbH n=443
NCT04102007 COMPLETED
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
AbbVie n=244
NCT02471144 COMPLETED
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
Novartis Pharmaceuticals n=162
NCT04728360 COMPLETED
Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis
Bio-Thera Solutions n=556
NCT04673786 COMPLETED
A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
Celltrion n=509
NCT03897088 COMPLETED
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
Sun Pharmaceutical Industries Limited n=231
NCT05108766 COMPLETED
A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
Shenzhen Kangzhe Pharmaceutical Co., Ltd. n=220
NCT03556202 TERMINATED
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
Eli Lilly and Company n=1,936
NCT04167462 COMPLETED
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea
Bristol-Myers Squibb n=220
NCT05120297 COMPLETED
A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis
Akeso n=452
NCT04595409 COMPLETED
A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis
Bioeq GmbH n=392
NCT04930042 COMPLETED
Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis
Alvotech Swiss AG n=581
NCT03624127 COMPLETED
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
Bristol-Myers Squibb n=666
NCT03611751 COMPLETED
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
Bristol-Myers Squibb n=1,020
NCT04211363 COMPLETED
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Arcutis Biotherapeutics, Inc. n=439
NCT04211389 COMPLETED
Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Arcutis Biotherapeutics, Inc. n=442
NCT03219437 COMPLETED
A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
AbbVie n=104
NCT03924427 COMPLETED
An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis
Bristol-Myers Squibb n=74
NCT00658788 COMPLETED
Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis
Galderma R&D n=305
NCT03168256 COMPLETED
CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
Can-Fite BioPharma n=528
NCT03390101 COMPLETED
An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis
Biocad n=213
NCT04453137 COMPLETED
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
Alvotech Swiss AG n=567
NCT01722331 COMPLETED
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
Sun Pharmaceutical Industries Limited n=772
NCT01194219 COMPLETED
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
Amgen n=844
NCT01232283 COMPLETED
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.
Amgen n=413
NCT01690299 COMPLETED
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
Amgen n=250
NCT01729754 COMPLETED
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
Sun Pharmaceutical Industries Limited n=1,090
NCT05174598 COMPLETED
A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis
Cadila Pharnmaceuticals n=278
NCT01936688 WITHDRAWN
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
Sun Pharmaceutical Industries Limited
NCT03930186 COMPLETED
A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
Amgen n=152
NCT03051217 COMPLETED
A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
UCB Biopharma S.P.R.L. n=127
NCT03998683 COMPLETED
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
Janssen-Cilag Ltd. n=117
NCT03022045 COMPLETED
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
AbbVie n=18
NCT02698475 COMPLETED
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
Janssen Research & Development, LLC n=44
NCT03504852 COMPLETED
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
Novartis Pharmaceuticals n=331
NCT03589885 COMPLETED
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
Novartis Pharmaceuticals n=122
NCT03073200 COMPLETED
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
Eli Lilly and Company n=201
NCT02762955 COMPLETED
Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis
Biocad n=344
NCT02684357 COMPLETED
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
AbbVie n=577
NCT02694523 COMPLETED
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
AbbVie n=684
NCT02684370 COMPLETED
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
AbbVie n=560
NCT02207231 COMPLETED
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Janssen Research & Development, LLC n=837
NCT02207244 COMPLETED
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
Janssen Research & Development, LLC n=992
NCT02346240 COMPLETED
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
UCB Biopharma S.P.R.L. n=559
NCT03210259 COMPLETED
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
Boehringer Ingelheim n=259
NCT03478787 COMPLETED
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
AbbVie n=327
NCT03364309 COMPLETED
A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
Eli Lilly and Company n=438
NCT03540160 TERMINATED
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
Vyne Therapeutics Inc. n=558
NCT03875508 COMPLETED
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
AbbVie n=108
NCT03535194 COMPLETED
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
Eli Lilly and Company n=1,484
NCT03875482 COMPLETED
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
AbbVie n=157
NCT03518047 COMPLETED
Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation
AbbVie n=50
NCT01365455 COMPLETED
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
Novartis Pharmaceuticals n=738
NCT02267135 COMPLETED
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
Novartis Pharmaceuticals n=102
NCT01358578 COMPLETED
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
Novartis Pharmaceuticals n=1,306
NCT03802344 COMPLETED
This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream
MC2 Therapeutics n=498
NCT03482011 COMPLETED
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
Eli Lilly and Company n=530
NCT02462122 COMPLETED
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Bausch Health Americas, Inc. n=215
NCT02899962 COMPLETED
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
LEO Pharma n=722
NCT02462070 COMPLETED
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Bausch Health Americas, Inc. n=203
NCT03731091 COMPLETED
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).
Glenmark Pharmaceuticals Ltd. India n=494
NCT01646177 COMPLETED
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
Eli Lilly and Company n=1,346
NCT03849404 COMPLETED
Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis
Alvotech Swiss AG n=413
NCT01597245 COMPLETED
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
Eli Lilly and Company n=1,224
NCT02561806 COMPLETED
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
Eli Lilly and Company n=302
NCT02513550 COMPLETED
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
Eli Lilly and Company n=1,257
NCT02325219 COMPLETED
An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis
Janssen Pharmaceutical K.K. n=192
NCT03123471 COMPLETED
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
Amgen n=303
NCT02489227 COMPLETED
Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
Coherus Oncology, Inc. n=545
NCT02951533 COMPLETED
A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Janssen-Cilag G.m.b.H n=119
NCT03731052 COMPLETED
Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)
Therapeutics, Inc. n=217
NCT03759197 COMPLETED
A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis
Therapeutics, Inc. n=206
NCT02514577 COMPLETED
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
Bausch Health Americas, Inc. n=217
NCT02515097 COMPLETED
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
Bausch Health Americas, Inc. n=213
NCT02462083 COMPLETED
Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Bausch Health Americas, Inc. n=555
NCT01708603 TERMINATED
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
Bausch Health Americas, Inc. n=1,831
NCT01708590 TERMINATED
Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
Bausch Health Americas, Inc. n=661
NCT01708629 TERMINATED
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
Bausch Health Americas, Inc. n=1,881
NCT03066609 COMPLETED
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Novartis Pharmaceuticals n=543
NCT02326298 COMPLETED
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
UCB Biopharma S.P.R.L. n=234
NCT02343744 COMPLETED
An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Janssen Pharmaceutical K.K. n=21
NCT02672852 COMPLETED
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
AbbVie n=507
NCT02634801 COMPLETED
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
Eli Lilly and Company n=162
NCT01474512 COMPLETED
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company n=1,296
NCT02326272 COMPLETED
A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
UCB Biopharma S.P.R.L. n=227
NCT03090100 COMPLETED
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Janssen Research & Development, LLC n=1,048
NCT01777191 COMPLETED
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
Eli Lilly and Company n=204
NCT02387801 COMPLETED
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
Eli Lilly and Company n=12
NCT02718898 COMPLETED
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
Eli Lilly and Company n=149
NCT03255382 COMPLETED
A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
AbbVie n=120
NCT01445886 COMPLETED
Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis
Yin-ku Lin n=33
NCT01624233 COMPLETED
A Study in Japanese Participants With Moderate-to-Severe Psoriasis
Eli Lilly and Company n=91
NCT00999687 COMPLETED
Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails
Chang Gung Memorial Hospital n=31
NCT02748863 COMPLETED
Study of Secukinumab With 2 mL Pre-filled Syringes
Novartis Pharmaceuticals n=214
NCT02826603 COMPLETED
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
Novartis Pharmaceuticals n=1,114
NCT02474069 COMPLETED
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
Novartis Pharmaceuticals n=772
NCT02134210 COMPLETED
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
Coherus Oncology, Inc. n=521
NCT02409667 COMPLETED
Plaque Psoriasis Efficacy and Safety With Secukinumab
Novartis Pharmaceuticals n=16,487
NCT02595970 COMPLETED
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
Novartis Pharmaceuticals n=120
NCT01815424 COMPLETED
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Pfizer n=266
NCT01970488 COMPLETED
Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis
Amgen n=350
NCT01961609 COMPLETED
Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.
Novartis Pharmaceuticals n=235
NCT01952015 COMPLETED
Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
Novartis Pharmaceuticals n=12
NCT02850965 COMPLETED
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Boehringer Ingelheim n=318
NCT02533375 COMPLETED
Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
AbbVie n=10
NCT01695239 COMPLETED
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis
Eli Lilly and Company n=417
NCT02008890 COMPLETED
Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
Novartis Pharmaceuticals n=237
NCT02362789 COMPLETED
Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers
Novartis Pharmaceuticals n=132
NCT01241591 COMPLETED
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer n=1,101
NCT01186744 COMPLETED
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer n=666
NCT03331523 COMPLETED
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis
Glenmark Pharmaceuticals Ltd. India n=643
NCT01544595 COMPLETED
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
Novartis Pharmaceuticals n=1,147
NCT02618759 COMPLETED
Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
Sun Pharmaceutical Industries, Inc. n=119
NCT02932462 COMPLETED
Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis
Sun Pharmaceutical Industries, Inc. n=373
NCT02933866 COMPLETED
Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis
Sun Pharmaceutical Industries, Inc. n=371
NCT02368210 COMPLETED
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)
Therapeutics, Inc. n=151
NCT02742441 COMPLETED
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)
Therapeutics, Inc. n=409
NCT02367911 COMPLETED
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis
Therapeutics, Inc. n=144
NCT02581345 COMPLETED
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
Momenta Pharmaceuticals, Inc. n=572
NCT01636687 COMPLETED
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
Novartis Pharmaceuticals n=182
NCT02886702 COMPLETED
A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis
Fougera Pharmaceuticals Inc. n=855
NCT01555125 COMPLETED
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
Novartis Pharmaceuticals n=177
NCT01235442 COMPLETED
Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Amgen n=592
NCT01640951 COMPLETED
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Novartis Pharmaceuticals n=675
NCT02445807 COMPLETED
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis
Promius Pharma, LLC n=265
NCT02635204 COMPLETED
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis
Promius Pharma, LLC n=267
NCT02196701 COMPLETED
Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study
AbbVie n=46
NCT01807520 COMPLETED
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
Novartis Pharmaceuticals n=198
NCT02606760 COMPLETED
Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis
Polichem S.A. n=378
NCT01806597 COMPLETED
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
Novartis Pharmaceuticals n=205
NCT03079973 WITHDRAWN
Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s
Polichem S.A.
NCT03202004 WITHDRAWN
GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis
GlaxoSmithKline
NCT02474082 COMPLETED
Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.
Novartis Pharmaceuticals n=202
NCT01251614 COMPLETED
A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate
AbbVie (prior sponsor, Abbott) n=114
NCT02203032 COMPLETED
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Janssen Research & Development, LLC n=872
NCT02074982 COMPLETED
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
Novartis Pharmaceuticals n=676
NCT02559622 COMPLETED
Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
Novartis Pharmaceuticals n=151
NCT01163253 TERMINATED
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer n=2,867
NCT01206387 COMPLETED
Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
Sun Pharmaceutical Industries, Inc. n=120
NCT02016482 COMPLETED
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
AbbVie n=217
NCT02016105 COMPLETED
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira
Sandoz n=465
NCT02795416 WITHDRAWN
Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population
Novartis Pharmaceuticals
NCT00833053 TERMINATED
Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)
Merck Sharp & Dohme LLC n=39
NCT01891864 COMPLETED
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel
Sandoz n=531
NCT01313221 COMPLETED
Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis
Amgen n=310
NCT01882647 COMPLETED
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
Therapeutics, Inc. n=222
NCT01550744 COMPLETED
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
Janssen Biotech, Inc. n=478
NCT01139580 COMPLETED
The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis
Stiefel, a GSK Company n=363
NCT00688519 COMPLETED
Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies
Stiefel, a GSK Company n=336
NCT02160665 COMPLETED
Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis
G & W Laboratories Inc. n=866
NCT00689481 COMPLETED
Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies
Stiefel, a GSK Company n=323
NCT02902861 COMPLETED
Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP)
Prof. Kristian Reich n=120
NCT01815723 WITHDRAWN
Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis
Forward-Pharma GmbH
NCT02786732 TERMINATED
Study to Evaluate Broadlumab vs Placebo and Ustekinumab
MedDerm Associates n=15
NCT01871402 COMPLETED
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)
Therapeutics, Inc. n=221
NCT01989429 COMPLETED
Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients
Maruho Europe Limited n=788
NCT01527097 WITHDRAWN
Influence of Atorvastatin on Psoriasis Severity and Endothelial Function
shmuel fuchs
NCT01908595 COMPLETED
Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
Maruho North America Inc. n=480
NCT01878461 COMPLETED
Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
Maruho North America Inc. n=542
NCT01873677 COMPLETED
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
Maruho North America Inc. n=537
NCT01519089 COMPLETED
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Pfizer n=95
NCT01406938 COMPLETED
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
Novartis Pharmaceuticals n=967
NCT01412944 COMPLETED
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
Novartis Pharmaceuticals n=43
NCT01782937 COMPLETED
An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis
Kyowa Kirin Co., Ltd. n=30
NCT01090427 COMPLETED
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
Janssen Research & Development, LLC n=110
NCT01646073 COMPLETED
Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis
AbbVie (prior sponsor, Abbott) n=425
NCT01765985 COMPLETED
Treatment of Palmoplantar Psoriasis With Low Doses Interferential Current
Pr PASSERON n=36
NCT01309737 COMPLETED
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer n=960
NCT01276639 COMPLETED
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer n=901
NCT01177800 COMPLETED
A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis
Xian-Janssen Pharmaceutical Ltd. n=129
NCT01206660 COMPLETED
Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
Sun Pharmaceutical Industries, Inc. n=120
NCT00723528 COMPLETED
An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis
Janssen Pharmaceutical K.K. n=158
NCT01321164 COMPLETED
Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis
Medical University of Vienna n=30
NCT01008995 COMPLETED
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis
Centocor, Inc. n=322
NCT01900782 WITHDRAWN
Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.
Novartis Pharmaceuticals
NCT01001208 COMPLETED
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis
Amgen n=478
NCT01091051 TERMINATED
Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis
Innovaderm Research Inc. n=33
NCT00747344 COMPLETED
A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
Centocor, Inc. n=121
NCT00626002 COMPLETED
Open Label Continuation Study in Moderate to Severe Psoriasis
AbbVie (prior sponsor, Abbott) n=2,301
NCT00679731 COMPLETED
A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
AbbVie (prior sponsor, Abbott) n=317
NCT00691964 COMPLETED
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
AbbVie (prior sponsor, Abbott) n=347
NCT00710580 COMPLETED
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
AbbVie (prior sponsor, Abbott) n=350
NCT01763424 COMPLETED
Nicotinamide in the Treatment of Psoriasis
Isfahan University of Medical Sciences n=66
NCT00747032 WITHDRAWN
To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis
Fougera Pharmaceuticals Inc.
NCT00566722 COMPLETED
Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy
Abbott n=152
NCT00715975 COMPLETED
Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis
Azidus Brasil n=140
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only